- Home
- WELL vs NVO Comparison
WELL vs NVO Comparison
Compare WELL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WELL | NVO |
|---|---|---|
| Founded | 1970 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7B | 203.2B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | WELL | NVO |
|---|---|---|
| Price | $240.98 | $48.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $224.38 | $51.00 |
| AVG Volume (30 Days) | 2.5M | ★ 12.4M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 1.40% | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $10,838,034,000.00 | N/A |
| Revenue This Year | $28.56 | N/A |
| Revenue Next Year | $6.97 | $3.70 |
| P/E Ratio | $235.36 | ★ $13.60 |
| Revenue Growth | ★ 35.63 | N/A |
| 52 Week Low | $163.75 | $35.12 |
| 52 Week High | $255.20 | $64.16 |
Technical Indicators
Market Signals| Indicator | WELL | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 54.56 |
| Support Level | $226.67 | $47.93 |
| Resistance Level | $255.20 | $50.45 |
| Average True Range (ATR) | 4.20 | 0.95 |
| MACD | 0.27 | 0.13 |
| Stochastic Oscillator | 80.68 | 94.29 |
Price Performance
Historical ComparisonAbout WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,800 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 900 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.